Back to top
more

Bruker (BRKR)

(Delayed Data from NSDQ)

$63.32 USD

63.32
931,004

-0.05 (-0.08%)

Updated Sep 10, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Instruments - Scientific

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Earnings Season Could Be Great for Bruker (BRKR)

by Zacks Equity Research

Bruker (BRKR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Bruker (BRKR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Bruker (BRKR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Bruker (BRKR) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Industry Outlook Highlights: Mettler-Toledo International, Waters Corp, PerkinElmer and Bruker

by Zacks Equity Research

Zacks Industry Outlook Highlights: Mettler-Toledo International, Waters Corp, PerkinElmer and Bruker

Aniruddha Ganguly headshot

4 Stocks to Watch on Rising Demand for Scientific Instruments

by Aniruddha Ganguly

The Zacks Instruments - Scientific industry is gaining from strong life science, pharmaceutical and academic end-market demand. Industry participants MTD, WAT, PKI, and BRKR are set to gain from rising healthcare spending and exposure to developing economies like China and India.

Bruker (BRKR) Launches PCR Panel, Expands Testing Portfolio

by Zacks Equity Research

Bruker's (BRKR) winter four-plex panel is expected to facilitate diagnosis and patient management by facilitating the use of saliva samples as well.

Bruker (BRKR) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Bruker (BRKR) is optimistic about maintaining a robust product portfolio along with its continued COVID-19-led progress.

Why Is Bruker (BRKR) Up 17.1% Since Last Earnings Report?

by Zacks Equity Research

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bruker's (BRKR) Q3 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Bruker's (BRKR) third-quarter 2020 results reflect dismal performances by two of the reporting segments and geographies due to coronavirus-led business disruptions.

Bruker (BRKR) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Bruker (BRKR) delivered earnings and revenue surprises of 27.27% and 5.27%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Bruker (BRKR) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bruker Rides on Nano and MALDI Launches Despite Margin Debacle

by Zacks Equity Research

Bruker (BRKR) has several Bruker NANO products that are being assembled and tested in Malaysia.

Bruker's Buyout of Canopy Biosciences Enhances Portfolio

by Zacks Equity Research

Bruker (BRKR) expands its multi-dimensional immune profiling by adding ChipCytometry tools via the acquisition of Canopy Biosciences.

The Zacks Analyst Blog Highlights: Mettler-Toledo, PerkinElmer, Waters and Bruker

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Mettler-Toledo, PerkinElmer, Waters and Bruker

Bruker Banks on Strategic Innovation Amid Coronavirus Crisis

by Zacks Equity Research

At Bruker's (BRKR) Germany campus, the company currently offers a pilot COVID-19 at work testing program for its factory workforce.

Aniruddha Ganguly headshot

4 Stocks to Watch on Rising Demand for Scientific Instruments

by Aniruddha Ganguly

The Zacks Instruments - Scientific industry is gaining from strong life science, pharmaceutical and academic end-market demand. Industry participants MTD, PKI, WAT and BRKR are set to gain from rising healthcare spending and exposure to developing economies like China and India.

Why Is Bruker (BRKR) Down 4.5% Since Last Earnings Report?

by Zacks Equity Research

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bruker Rides on MALDI Launches Amid Coronavirus-Led Crisis

by Zacks Equity Research

For higher specific detection of the SARS-CoV-2 virus, Bruker (BRKR) launches luoroType SARS-CoV-2 plus next-generation 6-plex PCR assay.

    Bruker (BRKR) Q2 Earnings Surpass Estimates, Margins Fall

    by Zacks Equity Research

    Bruker's (BRKR) second-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.

    Badger Meter (BMI) Q2 Earnings & Revenues Miss Estimates

    by Zacks Equity Research

    Thanks to COVID-19 related uncertainties, Badger Meter's (BMI) second-quarter 2020 earnings and revenues decline year over year with lower demand across various end-markets.

    Why Is Bruker (BRKR) Up 7.5% Since Last Earnings Report?

    by Zacks Equity Research

    Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Bruker Rides on PCI Sales, Coronavirus-Led Supply Issues Hurt

    by Zacks Equity Research

    Bruker (BRKR) expects a rise in sales within life science, biopharma and basic medical research, as well as in infectious disease diagnostics due to the pandemic.

    New Strong Sell Stocks for May 28th

    by Zacks Equity Research

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

    Bruker (BRKR) Q1 Earnings Miss Estimates, Guidance Suspended

    by Zacks Equity Research

    Bruker's (BRKR) first-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.

    Bruker (BRKR) Q1 Earnings and Revenues Lag Estimates

    by Zacks Equity Research

    Bruker (BRKR) delivered earnings and revenue surprises of -36.36% and -1.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?